




RealRate

PHARMACEUTICAL 2016

Crescent Biopharma INC
Rank 84 of 295

GlycoMimetics, Inc.
Innovation Today, Healing Tomorrow.



The relative strengths and weaknesses of Crescent Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Crescent Biopharma INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Crescent Biopharma INC is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 347%, being 84% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	47,244
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,747
Liabilities, Non-Current	0
Other Assets	697
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	244
Other Net Income	15
Other Revenues	20,071
Property and Equipment	521
Research and Development	25,050
Selling, General and Administrative Expense	7,805

Output Variable	Value in 1000 USD
Assets	48,462
Liabilities	7,991
Expenses	32,856
Revenues	20,071
Stockholders Equity	40,472
Net Income	-12,769
Comprehensive Net Income	-12,769
BaseVar	54,697
ECR before LimitedLiability	267%
Economic Capital Ratio	347%